

Dear Shareholder

Notice to Ineligible Shareholders of Renounceable Entitlement Offer

You are a holder of fully paid ordinary shares in the capital of Osteopore Limited (**Company**) as at today's date with a registered address outside of Australia, New Zealand, Malaysia and Singapore.

On 13 March 2024 the Company announced that it seeks to raise up to approximately \$3,000,000, before costs, from the issue of up to 103,286,890 fully paid ordinary shares (**New Shares**) and 20,657,378 free attaching options to subscribe for shares, via a pro rata renounceable rights offer (**Offer of RRI**).

Under the Offer, for every one (1) share held, Eligible Shareholders (being shareholders with an address in Australia, New Zealand, Malaysia and Singapore as at 18 March 2024 (**Record Date**)) will be entitled (**Entitlement**) to subscribe for ten (10) New Shares. With every five (5) New Shares issued, shareholders will receive one (1) free attaching unlisted option (**Option**). Each Option will be exercisable at \$0.0387 and have a term of 24 months from the Offer closing date.

In addition to subscribing for their Entitlements, Eligible Shareholders may apply for the shortfall. Subject to the overriding decision of the Board to determine the allocation of the shortfall as it sees fit, the Company intends to give priority to applications received from Eligible Shareholders.

The Entitlement Issue is made pursuant to a prospectus lodged with the Australian Securities and Investments Commission (**ASIC**) on 13 March 2024 (**Prospectus**) and released to the Australian Securities Exchange (**ASX**) on the same date. The Prospectus is available on the Company's website www.osteopore.com or on the ASX website (company announcements section, ASX code: OSX) www.asx.com.au.

It is anticipated that the Company will send a communication to all Eligible Shareholders in Australia, New Zealand, Malaysia and Singapore on 19 March 2024 via their preferred communication preference which will contain instruction on how to access their personalised Entitlement and Acceptance Form and participate in the offer.

Ineligible Shareholders

A shareholder who has a registered address outside of Australia, New Zealand, Malaysia and Singapore will not be eligible to participate in the Offer (**Ineligible Shareholder**).

You are not eligible to participate in the Offer and you will not be sent a copy of the Prospectus. This decision has been made pursuant to Listing Rule 7.7.1(a) of the ASX Listing Rules after taking into consideration the costs of complying with legal and regulatory requirements in jurisdictions outside of Australia, New Zealand, Malaysia and Singapore compared with the small number of Ineligible Shareholders and the number and value of Shares to which they would otherwise be entitled under the Offer.

The Company has appointed ACNS Capital Markets Pty Ltd, trading as Alto Capital, as nominee to sell the rights to subscribe for securities pursuant to the Prospectus (**Entitlements**) to which Ineligible Shareholders are entitled (**Nominee**). The Nominee will have the absolute and sole discretion to determine the timing and price at which the Entitlements may be sold and the manner of any such sale.

Any interest earned on the proceeds of the sale of these Entitlements will firstly be applied against expenses of such sale, including brokerage, and any balance will accrue to Ineligible Shareholders.

The net proceeds of the sale of these Entitlements will then be forwarded by the Company as soon as practicable to the Ineligible Shareholders, in proportion to their share of such Entitlements (after deducting brokerage commission and other expenses). If any such net proceeds of sale are less than the reasonable costs that would be incurred by the Company for distributing those proceeds, such proceeds may be retained by the Company.

Notwithstanding that the Nominee may sell Entitlements, Ineligible Shareholders may nevertheless receive no net proceeds if the costs of the sale are greater than the sale proceeds.

There is no guarantee that the Nominee will be able to sell Entitlements of Ineligible Shareholders on ASX and Ineligible Shareholders may receive no value for the Entitlements. Both the Company and the Nominee take no responsibility for the outcome of the sale of such Entitlements or the failure to sell such Entitlements.

Thank you for your ongoing support of the Company, and if you have any questions in relation to the above, please direct your enquiries to the Company Secretary by telephone on +61 2 8072 1400.

Yours faithfully



Mark Leong
Executive Chairman
Osteopore Limited